Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SCTC21C in combination with Bortezomib, Cyclophosphamide, and Dexamethasone for newly diagnosed systemic light-chain amyloidosis is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Light Chain Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• SCTC21C

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Amyloidosis | Phase 3 | Status: RECRUITING